The first thing to remember is that everybody with a diagnosis of scleroderma is at risk of developing lung disease — either interstitial lung disease (ILD), which affects about 60 […]
LEAP Rounds – Fall 2019
News
Automated Detection of Erythema Migrans in early Lyme disease, and Other Confounding Skin Lesions, via Deep Learning
Summary The study shows that deep machine learning can be utilized to more accurately identify erythema migrans rashes in early Lyme disease. Recognition of the EM rash is crucial to […]
PET Imaging of Glial Activation in Patients with Post Treatment Lyme Disease
This study uses a neuroimaging radiotracer with positron emission tomography (PET) to quantify cerebral glial activation in brains of patients with post-treatment Lyme disease. Results show elevated central nervous system immune activation in patients with PTLDS as compared to controls.
Myositis Patients, Caregivers, and Healthcare Providers Weigh-in About What is Most Important to Them
Our results indicate that substantial differences exist in how myositis is perceived by patients compared to healthcare providers, with different items prioritized.
Dermatomyositis Autoantibodies associated with adverse skin reactions after treatment
Hydroxychloroquine sulfate is frequently used to treat patients with dermatomyositis. It has been associated with an increased risk of adverse skin reactions in these patients.
EnCOMPASSing the extent of “dysautonomia” in patients with Scleroderma
This study explores the prevalence and risk factors for “autonomic dysfunction” in scleroderma.
